Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: James F. Hopkins who wrote (668)	11/15/1999 10:44:00 PM
From: Gary Korn	Read Replies (1) \| Respond to of 10345

11/15/99 Prof. Inv. Rep. 08:21:00 Professional Investor Report Copyright (c) 1999, Dow Jones & Company, Inc. Monday, November 15, 1999 Analysts' Ratings: Pharmaceuticals This is a weekly ranking of the stocks within the Pharmaceuticals industry, based on analysts' recommendations contributed within the past month to First Call's database. To be included on the list, a company must be rated by at least five analysts. Also included in the list are First Call analysts' estimates for the companies' current quarters. Estimates are operating income per share based on a survey of analysts. First Call Consensus Recommendation Scale 1.0-2.4 = Buy 2.5-3.4 = Hold 3.5-5.0 = Sell Latest # Analysts First Call # Analysts Consensus Covering EPS Estimate Covering --------- ---------- ------------ ---------- (Q: GLFD) 1.0 6 ($0.20) 4Q 6 (Q: PGNX) 1.2 5 $0.03 4Q 5 (Q: MRX) 1.3 8 $0.33 2Q 8 (N: ALO) 1.4 7 $0.40 4Q 6 (Q: ADRX) 1.5 6 $0.56 4Q 5 (N: BRL) 1.6 5 $0.53 2Q 5 (Q: INHL) 1.6 7 ($0.48) 4Q 7 (Q: QLTI) 1.6 14 ($0.10) 3Q 9 (A: FRX) 1.6 16 $0.34 3Q 15 (A: IVX) 1.7 6 $0.13 4Q 5 (Q: JMED) 1.7 6 $0.28 4Q 5 (Q: CLTR) 1.7 7 ($0.79) 4Q 7 (N: BVF) 1.7 12 $0.84 4Q 7 (Q: TEVA) 1.7 12 $0.61 4Q 11 (Q: SANG) 1.8 6 ($0.40) 4Q 5 (Q: SEPR) 1.8 11 ($1.30) 4Q 9 (N: WPI) 1.8 12 $0.45 4Q 10 (N: AHP) 1.8 23 $0.46 4Q 18 (N: WLA) 1.8 24 $0.52 4Q 20 (Q: BCHE) 1.9 19 $0.22 3Q 11 (Q: KING) 2.0 5 $0.40 4Q 5 (A: RPC) 2.0 5 $0.25 4Q 4 (N: ELN) 2.0 13 $0.35 4Q 12 (N: PNU) 2.1 19 $0.50 4Q 17 (N: SGP) 2.1 24 $0.33 4Q 22 (N: JNJ) 2.1 25 $0.57 4Q 22 (N: BMY) 2.1 27 $0.51 4Q 23 (N: AGN) 2.2 9 $0.77 4Q 8 (N: MRK) 2.2 26 $0.66 4Q 23 (N: LLY) 2.2 27 $0.61 4Q 22 (N: HOE) 2.3 6 N.A. 3Q 0 (Q: NVTSY) 2.3 9 N.A. 3Q 0 (N: PFE) 2.3 26 $0.22 4Q 23 (N: MYL) 2.4 11 $0.31 3Q 12 (N: GLX) 2.4 18 N.A. 3Q 0 (N: AZA) 2.5 8 $0.45 4Q 7 (Q: PGNS) 2.6 7 $0.02 4Q 6 (N: NVO) 2.7 7 $0.69 3Q 1 (N: SBH) 2.7 14 $0.54 4Q 4 08:21 AM EST

To: James F. Hopkins who wrote (668)	11/16/1999 2:00:00 PM
From: Paul Senior	Read Replies (1) \| Respond to of 10345

Hi Cap'n Jim! Looks like my first response got lost. Trying again. Yes, you are right, Yahoo is not accurate. quicken.excite.com I find ELN an impossible stock to analyze. Too many drugs, too many competitors, their different drug delivery system(s), plus now the the accounting questions. However, given their history, their size, their goals, the nature of the drug business (I can't analyze Bristol Myers either, and it's been a good investment for me anyway), I have been adding to my small position in ELN as stock has come down to new lows. Paul Senior